Serotonin, pregnancy and increased autism prevalence: Is there a link?

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 880-883

  Hadjikhani, Nouchine ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; OXYTOCIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

AMYGDALOID NUCLEUS; ARTICLE; AUTISM; BRAIN DEVELOPMENT; BRAIN DYSFUNCTION; CLINICAL FEATURE; DRUG CONTRAINDICATION; ENVIRONMENTAL FACTOR; FETUS DEVELOPMENT; HEREDITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHESIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PREGNANCY; PREVALENCE; RODENT;

AMYGDALA; AUTISTIC DISORDER; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; OXYTOCIN; PITUITARY-ADRENAL SYSTEM; PREGNANCY; SEROTONIN;

RODENTIA;

EID: 77951023387     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.11.015     Document Type: Article

References (65)

1. USCfDCa P. Prevalence of autism spectrum disorders: autism and developmental disabilities monitoring network. Surveillance Summaries, MMWR 2007, 56:1-40.
2. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009.
3. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr 2005, 94:2-15.
4. Rutter M. Aetiology of autism: findings and questions. J Intellect Disabil Res 2005, 49:231-238.
5. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin and human social behavior. Front Neuroendocrinol 2009.
6. Whitaker-Azmitia P.M. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism?. Int J Dev Neurosci 2005, 23:75-83.
7. Cook E.H., Arora R.C., Anderson G.M., Berry-Kravis E.M., Yan S.Y., Yeoh H.C., et al. Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 1993, 52:2005-2015.
8. Anderson G.M., Horne W.C., Chatterjee D., Cohen D.J. The hyperserotonemia of autism. Ann NY Acad Sci 1990, 600:331-340. discussion 341-332.
9. McBride P.A., Anderson G.M., Hertzig M.E., Snow M.E., Thompson S.M., Khait V.D., et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1998, 37:767-776.
10. Singh V.K., Singh E.A., Warren R.P. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 1997, 41:753-755.
11. Schain R.J., Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961, 58:315-320.
12. Cross S., Kim S.J., Weiss L.A., Delahanty R.J., Sutcliffe J.S., Leventhal B.L., et al. Molecular genetics of the platelet serotonin system in first-degree relatives of patients with autism. Neuropsychopharmacology 2008, 33:353-360.
13. Abramson R.K., Wright H.H., Carpenter R., Brennan W., Lumpuy O., Cole E., et al. Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord 1989, 19:397-407.
14. Cook E.H., Leventhal B.L., Heller W., Metz J., Wainwright M., Freedman D.X. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci 1990, 2:268-274.
15. Piven J., Tsai G.C., Nehme E., Coyle J.T., Chase G.A., Folstein S.E. Platelet serotonin: a possible marker for familial autism. J Autism Dev Disord 1991, 21:51-59.
16. Veenstra-VanderWeele J., Cook E.H. Knockout mouse points to second form of tryptophan hydroxylase. Mol Interv 2003, 3:72-75. 50.
17. Casanova M.F., Buxhoeveden D.P., Switala A.E., Roy E. Minicolumnar pathology in autism. Neurology 2002, 58:428-432.
18. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Jelliffe L.L., et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001, 49:597-606.
19. Green L., Fein D., Modahl C., Feinstein C., Waterhouse L., Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001, 50:609-613.
20. Modahl C., Green L., Fein D., Morris M., Waterhouse L., Feinstein C., et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998, 43:270-277.
21. McNamara I.M., Borella A.W., Bialowas L.A., Whitaker-Azmitia P.M. Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res 2008, 1189:203-214.
22. Sundstrom E., Kolare S., Souverbie F., Samuelsson E.B., Pschera H., Lunell N.O., et al. Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res 1993, 75:1-12.
23. Whitaker-Azmitia P.M., Azmitia E.C. Autoregulation of fetal serotonergic neuronal development: role of high affinity serotonin receptors. Neurosci Lett 1986, 67:307-312.
24. Jorgensen H., Kjaer A., Knigge U., Moller M., Warberg J. Serotonin stimulates hypothalamic mRNA expression and local release of neurohypophysial peptides. J Neuroendocrinol 2003, 15:564-571.
25. Davis E., Fennoy I., Laraque D., Kanem N., Brown G., Mitchell J. Autism and developmental abnormalities in children with perinatal cocaine exposure. J Natl Med Assoc 1992, 84:315-319.
26. Mann J.J. The medical management of depression. The New England journal of medicine 2005, 353:1819-1834.
27. Reefhuis J., Rasmussen S.A., Friedman J.M. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. New Engl J Med 2006, 354:2188-2190. author reply.
28. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-509.
29. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New Engl J Med 2007, 356:2684-2692.
30. Laine K., Heikkinen T., Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60:720-726.
31. Pastuszak A., Schick-Boschetto B., Zuber C., Feldkamp M., Pinelli M., Sihn S., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993, 269:2246-2248.
32. Borue X., Chen J., Condron B.G. Developmental effects of SSRIs: lessons learned from animal studies. Int J Dev Neurosci 2007, 25:341-347.
33. M.H. America, Ranking America's mental health: an analysis of depression across the states. Washington; 2007.
34. Chugani D.C., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999, 45:287-295.
35. Chugani D.C., Muzik O., Rothermel R., Behen M., Chakraborty P., Mangner T., et al. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 1997, 42:666-669.
36. Murphy D.G., Daly E., Schmitz N., Toal F., Murphy K., Curran S., et al. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry 2006, 163:934-936.
37. West L., Brunssen S.H., Waldrop J. Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs 2009, 14:183-191.
38. McDougle C.J., Naylor S.T., Goodman W.K., Volkmar F.R., Cohen D.J., Price L.H. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 1993, 33:547-550.
39. Williams J.H., Perrett D.I., Waiter G.D., Pechey S. Differential effects of tryptophan depletion on emotion processing according to face direction. Soc Cogn Affect Neurosci 2007, 2:264-273.
40. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
41. Miyazaki K., Narita N., Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 2005, 23:287-297.
42. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function and regulation. Physiol Rev 2001, 81:629-683.
43. Ferguson J.N., Young L.J., Insel T.R. The neuroendocrine basis of social recognition. Front Neuroendocrinol 2002, 23:200-224.
44. Winslow J.T., Insel T.R. The social deficits of the oxytocin knockout mouse. Neuropeptides 2002, 36:221-229.
45. Carter C.S. Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders. Behav Brain Res 2007, 176:170-186.
46. Lim M.M., Bielsky I.F., Young L.J. Neuropeptides and the social brain: potential rodent models of autism. Int J Dev Neurosci 2005, 23:235-243.
47. Hammock E.A., Young L.J. Oxytocin, vasopressin and pair bonding: implications for autism. Phil Trans Roy Soc London 2006, 361:2187-2198.
48. Israel S., Lerer E., Shalev I., Uzefovsky F., Riebold M., Laiba E., et al. The oxytocin receptor (OXTR) contributes to prosocial fund allocations in the dictator game and the social value orientations task. PLoS One 2009, 4:e5535.
49. Heinrichs M., Domes G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 2008, 170:337-350.
50. Domes G., Heinrichs M., Michel A., Berger C., Herpertz S.C. Oxytocin improves " mind-reading" in humans. Biol Psychiatry 2007, 61:731-733.
51. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005, 25:11489-11493.
52. Guastella A.J., Mitchell P.B., Dadds M.R. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 2008, 63:3-5.
53. Domes G., Heinrichs M., Glascher J., Buchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007, 62:1187-1190.
54. Rimmele U., Hediger K., Heinrichs M., Klaver P. Oxytocin makes a face in memory familiar. J Neurosci 2009, 29:38-42.
55. Bauman M., Kemper T.L. Histoanatomic observations of the brain in early infantile autism. Neurology 1985, 35:866-874.
56. Abell F., Krams M., Ashburner J., Passingham R., Friston K., Frackowiak R., et al. Neuroreport 1999, 10:1647-1651.
57. Howard M.A., Cowell P.E., Boucher J., Broks P., Mayes A., Farrant A., et al. Convergent neuroanatomical and behavioural evidence of an amygdala hypothesis of autism. Neuroreport 2000, 11:2931-2935.
58. Aylward E.H., Minshew N.J., Goldstein G., Honeycutt N.A., Augustine A.M., Yates K.O., et al. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology 1999, 53:2145-2150.
59. Pierce K., Muller R.A., Ambrose J., Allen G., Courchesne E. Face processing occurs outside the fusiform 'face area' in autism: evidence from functional MRI. Brain 2001, 124:2059-2073.
60. Nacewicz B.M., Dalton K.M., Johnstone T., Long M.T., McAuliff E.M., Oakes T.R., et al. Amygdala volume and nonverbal social impairment in adolescent and adult males with autism. Arch Gen Psychiatry 2006, 63:1417-1428.
61. Schumann C.M., Amaral D.G. Stereological analysis of amygdala neuron number in autism. J Neurosci 2006, 26:7674-7679.
62. Baron-Cohen S., Ring H.A., Wheelwright S., Bullmore E.T., Brammer M.J., Simmons A., et al. Social intelligence in the normal and autistic brain: an fMRI study. Eur J Neurosci 1999, 11:1891-1898.
63. Adolphs R., Sears L., Piven J. Abnormal processing of social information from faces in autism. J Cogn Neurosci 2001, 13:232-240.
64. Baron-Cohen S., Ring H.A., Bullmore E.T., Wheelwright S., Ashwin C., Williams S.C. The amygdala theory of autism. Neurosci Biobehav Rev 2000, 24:355-364.
65. Kocorowski L.H., Helmstetter F.J. Calcitonin gene-related peptide released within the amygdala is involved in Pavlovian auditory fear conditioning. Neurobiol Learn Mem 2001, 75:149-163.